Deletion of major nonessential genomic regions in the vaccinia virus lister strain enhances attenuation without altering vaccine efficacy in mice

Journal of Virology

Volumn 85, Issue 10, 2011, Pages 5016-5026

  Dimier, Julie ^a   Ferrier Rembert, Audrey ^a   Pradeau Aubreton, Karine ^b   Hebben, Matthias ^b,c   Spehner, Daniele ^b   Favier, Anne Laure ^a   Gratier, Danielle ^a   Garin, Daniel ^a   Crance, Jean Marc ^a   Drillien, Robert ^b  

^a CENTRE DE RECHERCHES   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c Vivalis   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; VACCINIA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STRAIN BHK; CELLULAR IMMUNITY; CONTROLLED STUDY; COWPOX; DRUG EFFICACY; FEMALE; GENE DELETION; HELA CELL; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS ATTENUATION; VIRUS GENOME; VIRUS MUTANT; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE; WEIGHT REDUCTION;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; COWPOX; COWPOX VIRUS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; SEQUENCE DELETION; SMALLPOX VACCINE; VACCINES, ATTENUATED; VACCINIA VIRUS; VIRUS REPLICATION;

COWPOX VIRUS; MUS; MUS MUSCULUS; VACCINIA VIRUS; VARIOLA VIRUS;

EID: 79955397463     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02359-10     Document Type: Article

References (77)

1. Alcami, A., A. Khanna, N. L. Paul, and G. L. Smith. 1999. Vaccinia virus strains Lister, USSR and Evans express soluble and cell-surface tumour necrosis factor receptors. J. Gen. Virol. 80:949-959.
2. Ali, A. N., P. C. Turner, M. A. Brooks, and R. W. Moyer. 1994. The SPI-1 gene of rabbitpox virus determines host range and is required for hemor-rhagic pock formation. Virology 202:305-314.
3. Amegadzie, B. Y., J. R. Sisler, and B. Moss. 1992. Frame-shift mutations within the vaccinia virus A-type inclusion protein gene. Virology 186:777-782.
4. Antoine, G., F. Scheiflinger, F. Dorner, and F. G. Falkner. 1998. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244:365-396.
5. Bartlett, N., J. A. Symons, D. C. Tscharke, and G. L. Smith. 2002. The vaccinia virus N1L protein is an intracellular homodimer that promotes virulence. J. Gen. Virol. 83:1965-1976.
6. Beard, P. M., G. C. Froggatt, and G. L. Smith. 2006. Vaccinia virus kelch protein A55 is a 64 kDa intracellular factor that affects virus-induced cyto-pathic effect and the outcome of infection in a murine intradermal model. J. Gen. Virol. 87:1521-1529.
7. Belyakov, I. M., et al. 2003. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc. Natl. Acad. Sci. U. S. A. 100:9458-9463.
8. Blanchard, T. J., A. Alcami, P. Andrea, and G. L. Smith. 1998. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J. Gen. Virol. 79:1159-1167.
9. Bowie, A., et al. 2000. A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc. Natl. Acad. Sci. U. S. A. 97:10162-10167.
10. Buller, R. M., G. L. Smith, K. Cremer, A. L. Notkins, and B. Moss. 1985. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 317:813-815.
11. Buttner, M., C. P. Czerny, K. H. Lehner, and K. Wertz. 1995. Interferon induction in peripheral blood mononuclear leukocytes of man and farm animals by poxvirus vector candidates and some poxvirus constructs. Vet. Immunol. Immunopathol. 46:237-250.
12. Davison, A. J., and B. Moss. 1989. Structure of vaccinia virus early promoters. J. Mol. Biol. 210:749-769.
13. Drillien, R., D. Spehner, and D. Hanau. 2004. Modified vaccinia virus Ankara induces moderate activation of human dendritic cells. J. Gen. Virol. 85:2167-2175.
14. Earl, P. L., et al. 2004. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428:182-185.
15. Earl, P. L., et al. 2008. Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc. Natl. Acad. Sci. U. S. A. 105:10889-10894.
16. Falkner, F. G., and B. Moss. 1990. Transient dominant selection of recombinant vaccinia viruses. J. Virol. 64:3108-3111.
17. Fenner, F., D. A. Henderson, I. Arita, Z. Jezek, and I. D. Ladnyi (ed.). 1988. Smallpox and its eradication. World Health Organization, Geneva, Switzerland.
18. Ferrier-Rembert, A., R. Drillien, B. Meignier, D. Garin, and J. M. Crance. 2007. Safety, immunogenicity and protective efficacy in mice of a new cell-cultured Lister smallpox vaccine candidate. Vaccine 25:8290-8297.
19. Ferrier-Rembert, A., R. Drillien, J. N. Tournier, D. Garin, and J. M. Crance. 2007. Intranasal cowpox virus infection of the mouse as a model for preclinical evaluation of smallpox vaccines. Vaccine 25:4809-4817.
20. Ferrier-Rembert, A., R. Drillien, J. N. Tournier, D. Garin, and J. M. Crance. 2008. Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine. Vaccine 26:1794-1804.
21. Franchini, M., et al. 2004. Dendritic cells from mice neonatally vaccinated with modified vaccinia virus Ankara transfer resistance against herpes simplex virus type I to naive one-week-old mice. J. Immunol. 172:6304-6312.
22. Garcel, A., J. M. Crance, R. Drillien, D. Garin, and A. L. Favier. 2007. Genomic sequence of a clonal isolate of the vaccinia virus Lister strain employed for smallpox vaccination in France and its comparison to other orthopoxviruses. J. Gen. Virol. 88:1906-1916.
23. Garcel, A., et al. 2008. Phenotypic and genetic diversity of the traditional Lister smallpox vaccine. Vaccine 27:708-717.
24. Gillard, S., D. Spehner, R. Drillien, and A. Kirn. 1986. Localization and sequence of a vaccinia virus gene required for multiplication in human cells. Proc. Natl. Acad. Sci. U. S. A. 83:5573-5577.
25. Gomez, C. E., J. L. Najera, M. Krupa, and M. Esteban. 2008. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr. Gene Ther. 8:97-120.
26. Gubser, C, et al. 2007. A new inhibitor of apoptosis from vaccinia virus and eukaryotes. PLoS Pathog. 3:e17.
27. Halsell, J. S., et al. 2003. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. JAMA 289:3283-3289.
28. Howard, A. R., A. S. Weisberg, and B. Moss. 2010. Congregation of orthopoxvirus virions in cytoplasmic A-type inclusions is mediated by interactions of a bridging protein (A26p) with a matrix protein (ATIp) and a virion membrane-associated protein (A27p). J. Virol. 84:7592-7602.
29. Howley, P. M., D. Spehner, and R. Drillien. 1996. A vaccinia virus transfer vector using a GUS reporter gene inserted into the I4L locus. Gene 172: 233-237.
30. Jackson, S. S., et al. 2005. Role of genes that modulate host immune responses in the immunogenicity and pathogenicity of vaccinia virus. J. Virol. 79:6554-6559.
31. Jentarra, G. M., et al. 2008. Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: scarification vaccination. Vaccine 26:2860-2872.
32. Karjalainen, J., et al. 1983. Etiology of mild acute infectious myocarditis. Relation to clinical features. Acta Med. Scand. 213:65-73.
33. Kato, S., M. Takahashi, S. Kameyama, and J. Kamahora. 1959. A study on the morphological and cyto-immunological relationship between the inclusions of variola, cowpox, rabbitpox, vaccinia (variola origin) and vaccinia IHD, and a consideration of the term "Guarnieri body." Biken J. 2:353-363.
34. Kotwal, G. J., and B. Moss. 1988. Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. Nature 335: 176-178.
35. Kretzschmar, M., J. Wallinga, P. Teunis, S. Xing, and R. Mikolajczyk. 2006. Frequency of adverse events after vaccination with different vaccinia strains. PLoS Med. 3:e272.
36. Lathe, R., J. L. Vilotte, and A. J. Clark. 1987. Plasmid and bacteriophage vectors for excision of intact inserts. Gene 57:193-201.
37. Lee, M. S., et al. 1992. Molecular attenuation of vaccinia virus: mutant generation and animal characterization. J. Virol. 66:2617-2630.
38. Legrand, F. A., et al. 2004. Induction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes. J. Virol. 78:2770-2779.
39. Leparc-Goffart, I., et al. 2005. Standardization of a neutralizing anti-vaccinia antibodies titration method: an essential step for titration of vaccinia immunoglobulins and smallpox vaccines evaluation. J. Clin. Virol. 32:47-52.
40. Liu, L., et al. 2010. Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity. Nat. Med. 16:224-227.
41. Martinez, M. J., M. P. Bray, and J. W. Huggins. 2000. A mouse model of aerosol-transmitted orthopoxviral disease: morphology of experimental aerosol-transmitted orthopoxviral disease in a cowpox virus-BALB/c mouse system. Arch. Pathol. Lab. Med. 124:362-377.
42. Mayr, A., and K. Danner. 1978. Vaccination against pox diseases under immunosuppressive conditions. Dev. Biol. Stand. 41:225-234.
43. McKelvey, T. A., S. C. Andrews, S. E. Miller, C. A. Ray, and D. J. Pickup. 2002. Identification of the orthopoxvirus p4c gene, which encodes a structural protein that directs intracellular mature virus particles into A-type inclusions. J. Virol. 76:11216-11225.
44. Meiser, A., C. Sancho, and J. Krijnse Locker. 2003. Plasma membrane budding as an alternative release mechanism of the extracellular enveloped form of vaccinia virus from HeLa cells. J. Virol. 77:9931-9942.
45. Meisinger-Henschel, C., et al. 2007. Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. J. Gen. Virol. 88:3249-3259.
46. Meisinger-Henschel, C., et al. 2010. Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice. J. Virol. 84:9907-9919.
47. Meng, X., et al. 2009. Vaccinia virus K1L and C7L inhibit antiviral activities induced by type I interferons. J. Virol. 83:10627-10636.
48. Meseda, C. A., et al. 2005. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology 339:164-175.
49. Meseda, C. A., et al. 2009. Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model. Clin. Vaccine Immunol. 16:1261-1271.
50. Meyer, H., G. Sutter, and A. Mayr. 1991. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72:1031-1038.
51. Midgley, C. M., M. M. Putz, J. N. Weber, and G. L. Smith. 2008. Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax. J. Gen. Virol. 89:2992-2997.
52. Moss, B. 2011. Smallpox vaccines: targets of protective immunity. Immunol. Rev. 239:8-26.
53. Najera, J. L., C. E. Gomez, J. Garcia-Arriaza, C. O. Sorzano, and M. Esteban. 2010. Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens. PLoS One 5:e11406.
54. Neyts, J., P. Leyssen, E. Verbeken, and E. De Clercq. 2004. Efficacy of cidofovir in a murine model of disseminated progressive vaccinia. Antimi-crob. Agents Chemother. 48:2267-2273.
55. Paran, N., et al. 2009. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox. J. Infect. Dis. 199:39-48.
56. Phelps, A. L., A. J. Gates, M. Hillier, L. Eastaugh, and D. O. Ulaeto. 2007. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine. Vaccine 25:34-42.
57. Pires de Miranda, M., P. C. Reading, D. C. Tscharke, B. J. Murphy, and G. L. Smith. 2003. The vaccinia virus kelch-like protein C2L affects calcium-independent adhesion to the extracellular matrix and inflammation in a murine intradermal model. J. Gen. Virol. 84:2459-2471.
58. Poirier, B., et al. 2005. Establishment of a national network of validated and qualified laboratories for neutralizing anti-vaccinia antibodies titration. Biologicals 33:277-282.
59. Ramshaw, I. A., M. E. Andrew, S. M. Phillips, D. B. Boyle, and B. E. Coupar. 1987. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recom-binant infection. Nature 329:545-546.
60. Reading, P. C., A. Khanna, and G. L. Smith. 2002. Vaccinia virus CrmE encodes a soluble and cell surface tumor necrosis factor receptor that contributes to virus virulence. Virology 292:285-298.
61. Sambrook, J., and D. W. Russell. 2001. Molecular cloning: a laboratory manual, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
62. Samuelsson, C., et al. 2008. Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J. Clin. Invest. 118:1776-1784.
63. Sancho, M. C., S. Schleich, G. Griffiths, and J. Krijnse-Locker. 2002. The block in assembly of modified vaccinia virus Ankara in HeLa cells reveals new insights into vaccinia virus morphogenesis. J. Virol. 76:8318-8334.
64. Shisler, J. L., S. N. Isaacs, and B. Moss. 1999. Vaccinia virus serpin-1 deletion mutant exhibits a host range defect characterized by low levels of intermediate and late mRNAs. Virology 262:298-311.
65. Staib, C, Y. Suezer, S. Kisling, U. Kalinke, and G. Sutter. 2006. Short-term, but not post-exposure, protection against lethal orthopoxvirus challenge after immunization with modified vaccinia virus Ankara. J. Gen. Virol. 87: 2917-2921.
66. Stickl, H., et al. 1974. MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA). Dtsch. Med. Wochenschr. 99:2386-2392.
67. Stittelaar, K. J., et al. 2005. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J. Virol. 79: 7845-7851.
68. Sutter, G., and B. Moss. 1992. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. U. S. A. 89:10847-10851.
69. Tamin, A., J. Esposito, and D. Hruby. 1991. A single nucleotide substitution in the 5'-untranslated region of the vaccinia N2Lgene is responsible for both alpha-amanitin-resistant and temperature-sensitive phenotypes. Virology 182:393-396.
70. + phenotypes of vaccinia virus recombinants after intranasal inoculation of mice. J. Gen. Virol. 72:125-130.
71. Vollmar, J., et al. 2006. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 24: 2065-2070.
72. Waibler, Z., et al. 2007. Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses. J. Virol. 81:12102-12110.
73. Williamson, J. D., R. W. Reith, L. J. Jeffrey, J. R. Arrand, and M. Mackett. 1990. Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route. J. Gen. Virol. 71:2761-2767.
74. Wyatt, L. S., et al. 1998. Marker rescue of the host range restriction defects of modified vaccinia virus Ankara. Virology 251:334-342.
75. Wyatt, L. S., P. L. Earl, L. A. Eller, and B. Moss. 2004. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc. Natl. Acad. Sci. U. S. A. 101:4590-4595.
76. Youn, J. W., et al. 2008. Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus. J. Virol. 82:10896-10905.
77. Zhu, W., et al. 2007. The attenuation of vaccinia Tian Tan strain by the removal of the viral M1L-K2L genes. J. Virol. Methods 144:17-26.